Real World Evidence In Europe - The Results Of An Expert Survey

Interest in Real World Evidence (RWE), data not collected via traditional randomised controlled trials used in different contexts, is increasing for market-access and reimbursement decision-makers. A global survey was undertaken to understand the use of RWE in these contexts. Whilst there are some d...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-10, Vol.20 (9), p.A655
Main Authors: Gill, JL, Albanell, J, Avouac, B, Dank, M, Duncombe, R, Fink-Wagner, A, Hutton, J, Jahnz-Rozyk, K, Kössler, I, Podrazilova, K, Schramm, W, Spandonaro, F, Vaz Carneiro, A, Wartenberg, M, Kanavos, P
Format: Article
Language:English
Subjects:
Access
Clinical trials
Data quality
Decision makers
Decision making
Polls & surveys
Reimbursement
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interest in Real World Evidence (RWE), data not collected via traditional randomised controlled trials used in different contexts, is increasing for market-access and reimbursement decision-makers. A global survey was undertaken to understand the use of RWE in these contexts. Whilst there are some differing opinions around the use of RWE for regulatory purposes, most respondents see it as a complement to RCT, rather than a replacement. The general opinion is that RWE will become more valuable over time if data quality and availability can be improved.
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2017.08.1554